Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Other financing activities (2014 - 2016)

Iradimed (IRMD) reported Other financing activities of $53122.0 for Q4 2016, down 93.75% year-over-year from $850449.0 in Q1 2016, and down 81.32% on a QoQ basis from $284337.0 in Q3 2016.

Iradimed (IRMD) has 3 years of Other financing activities data on file, last reported at $53122.0 in Q4 2016.

  • Quarterly Other financing activities fell 93.75% year-over-year to $53122.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $603553.0 (down 65.08% YoY) and the FY2025 annual result came in at -$1.1 million, down 763.36% from the prior year.
  • Other financing activities slipped to $53122.0 in Q4 2016 per IRMD's latest filing, from $284337.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.8 million in Q3 2014 and bottomed at $49807.0 in Q2 2015.
  • The 3-year median for Other financing activities is $209515.0 (2016), against an average of $463696.8.
  • Peak annual rise in Other financing activities reached 320.65% in 2016, while the deepest fall reached 93.75% in 2016.
  • Tracing IRMD's Other financing activities over 3 years: stood at $1.8 million in 2014, then sank by 53.81% to $850449.0 in 2015, then slumped by 93.75% to $53122.0 in 2016.
  • Per Business Quant, the three latest IRMD Other financing activities figures stand at $53122.0 (Q4 2016), $284337.0 (Q3 2016), and $209515.0 (Q2 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Iradimed 1.17 Bn 1.11 Bn 16.81 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2016 53,122.00
Dec 31, 2016 53,122.00
Sep 30, 2016 284,337.00
Sep 30, 2016 284,337.00
Jun 30, 2016 209,515.00
Jun 30, 2016 209,515.00
Mar 31, 2016 56,579.00
Mar 31, 2016 56,579.00
Dec 31, 2015 850,449.00
Dec 31, 2015 850,449.00
Sep 30, 2015 715,906.00
Sep 30, 2015 715,906.00
Jun 30, 2015 49,807.00
Jun 30, 2015 49,807.00
Mar 31, 2015 112,433.00
Mar 31, 2015 112,433.00
Sep 30, 2014 1.84 Mn
Sep 30, 2014 1.84 Mn